Clearpoint Neuro, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US18507C1036
USD
14.06
0.72 (5.4%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Clearpoint Neuro, Inc. stock-summary
stock-summary
Clearpoint Neuro, Inc.
Pharmaceuticals & Biotechnology
Clearpoint Neuro Inc, formerly MRI Interventions, Inc., MRI Interventions, Inc. is a medical device company. The Company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It has two product platforms: ClearPoint system, which is used to perform minimally invasive surgical procedures in the brain and ClearTrace system, which is under development, to be used to perform minimally invasive surgical procedures in the heart. Its ClearPoint system is a neuro-navigation system designed for placing catheters and electrodes to treat a range of neurological diseases and conditions and for performing biopsies. Its ClearTrace system is designed to deliver catheter-based therapies to treat certain cardiac diseases. Both systems utilize intra-procedural MRI to guide the procedures.
Company Coordinates stock-summary
Company Details
5 Musick , IRVINE CA : 92618-1638
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 24 Schemes (12.98%)

Foreign Institutions

Held by 36 Foreign Institutions (2.84%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kimble Jenkins
Chairman of the Board
Mr. Joseph Burnett
President, Chief Executive Officer, Director
Mr. R. John Fletcher
Lead Independent Director
Mr. Pascal Girin
Independent Director
Ms. B. Kristine Johnson
Independent Director
Dr. Matthew Klein
Independent Director
Mr. Timothy Richards
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 311 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.63

stock-summary
Return on Equity

-112.56%

stock-summary
Price to Book

15.74